Department of Radiation Oncology, West Virginia University, 1 Medical Center Dr., Morgantown, WV, 26505, USA.
Department of Neurosurgery, West Virginia University, Morgantown, WV, USA.
J Neurooncol. 2018 Nov;140(2):413-420. doi: 10.1007/s11060-018-2968-4. Epub 2018 Aug 9.
Post-operative SRS (stereotactic radiosurgery) for large brain metastases is challenged by risks of radiation necrosis that limit SRS dose. Intraoperative radiotherapy (IORT) is a potential alternative, however standard dose recommendations are lacking.
Twenty consecutive brain metastases treated with post-operative SRS were retrospectively compared to IORT plans generated for 10-30 Gy in 1 fraction to 0-5 mm by estimating the applicator size and distance from critical organs using pre-operative and post-operative MRI. Additionally, 7 consecutive patients treated with IORT 30 Gy to surface were compared to retrospectively generated SRS plans using the post-operative MRI to 15-20 Gy and 30 Gy in 1 fraction marginal dose.
For the 20 resection cavities treated with SRS and retrospectively compared to IORT, IORT from 10 to 30Gy resulted in lower or not significantly different doses to the optic apparatus and brainstem. Comparatively for the 7 patients treated with IORT 30 Gy to retrospective SRS plans to standard 15-20 Gy and 30 Gy marginal dose, IORT resulted in significantly lower doses to the optic apparatus and brainstem. At a median follow-up of 6.2 months, 86% of patients treated with surgery and IORT achieved local control and 0% developed radiographic or symptomatic radiation necrosis.
Critical organ dosimetry for IORT remains generally lower than that achieved with single fraction SRS following resection of large brain metastases. We recommend 30 Gy to surface as the preferred prescription, consistent with the dose recommendation for IORT in glioblastoma used in the ongoing INTRAGO-II phase-III trial. Early clinical outcomes appear promising for surgery and IORT.
术后立体定向放射外科(SRS)治疗大的脑转移瘤存在放射性坏死风险,限制了 SRS 剂量,因此具有挑战性。术中放疗(IORT)是一种潜在的替代方法,但缺乏标准剂量建议。
回顾性比较了 20 例接受术后 SRS 治疗的脑转移瘤患者,与 10-30Gy 单次分割至 0-5mm 的 IORT 计划进行比较,通过术前和术后 MRI 评估施源器大小和与关键器官的距离来估算。此外,对 7 例接受 30Gy 表面 IORT 的患者进行了前瞻性比较,采用术后 MRI 对 15-20Gy 和 30Gy 单次分割的边缘剂量进行回顾性 SRS 计划。
对于 20 例接受 SRS 治疗并与 IORT 进行回顾性比较的切除腔,IORT 从 10Gy 到 30Gy 导致视神经和脑干的剂量较低或无显著差异。对于 7 例接受 IORT 30Gy 治疗的患者,与标准的 15-20Gy 和 30Gy 边缘剂量的回顾性 SRS 计划相比,IORT 导致视神经和脑干的剂量显著降低。在中位随访 6.2 个月时,86%接受手术和 IORT 治疗的患者实现了局部控制,0%的患者发生放射性或症状性放射性坏死。
对于大的脑转移瘤切除术后,IORT 的关键器官剂量通常低于单次分割 SRS 治疗。我们推荐表面 30Gy 作为首选处方,与正在进行的 INTRAGO-II 期 III 期试验中用于胶质母细胞瘤的 IORT 剂量建议一致。手术和 IORT 的早期临床结果令人鼓舞。